Abstract
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare (occurring in approximately 2 to 3 people/million population/year in Europe and the US), life-threatening, intolerance reaction of the skin. It is most often caused by drugs (most commonly sulfonamides, nonsteroidal anti-inflammatory drugs, antimalarials, anticonvulsants, and allopurinol).
SJS/TEN is characterized by a macular exanthema (‘atypical targets’) which focusses on the face, neck, and the central trunk regions. Lesions show rapid confluence, a positive Nikolsky’s sign, and quickly result in widespread detachment of the epidermis and erosions. Mucosal, conjunctival, and anogenital mucous membranes are prominently involved. Histopathology shows satellite cell necrosis in the early stages progressing to full thickness necrosis of the epidermis, contrasting with rather inconspicuous inflammatory infiltrates of the dermis. Damage to the skin is thought to be mediated by cytotoxic T lymphocytes and mononuclear cells which induce apoptosis in keratinocytes expressing drug-derived antigens at their surfaces.
No guidelines for the treatment of SJS/TEN exist since no controlled clinical trials have ever been performed. The controversy over whether systemic corticosteroids should be used to curtail progression is still unresolved; while many authors agree that corticosteroids do in fact suppress progression, it is obvious that they also greatly enhance the risk of infection, the complication which most frequently leads to a fatal outcome. It appears reasonable to only administer corticosteroids in the phase of progression and to withdraw them as soon as possible, and to add antibacterials for prophylaxis. Recently, in a small series of patients, intravenous immunoglobulins were presumed to be effective by the blockade of lytic Fas ligand-mediated apoptosis in SJS/TEN. However, these results have to be confirmed by large clinical trials. Supportive treatment and monitoring of vital functions is of utmost importance in SJS/TEN, and out-patient treatment is unacceptable. Recovery is usually slow, depending on the extent and severity and the presence of complications, and may take 3 to 6 weeks. Skin lesions heal without scars as a rule, but scarring of mucosal sites is a frequent late complication, potentially leading to blindness, obliteration of the fornices and anogenital strictures.
There is no reliable laboratory test to determine the offending drug; diagnosis rests on the patient’s history and the empirical risk of drugs to elicit skin SJS/TEN. Provocation tests are not indicated since re-exposure is likely to elicit a new episode of SJS/TEN of increased severity.
Similar content being viewed by others
References
Bastuji-Garin S., Rzany B., Stern R.S., et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129 (1): 92–96
Roujeau J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102 (6): 28S–30S
Fritsch P.O., Ruiz-Maldonado R. Erythema nultiforme. In: Freedberg I.M., Eisen A.Z., Wolff K., et al., editors. Fitzpatrick’s Dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 636–644
Fritsch P.O., Ruiz-Maldonado R. Stevens-Johnson syndrome — toxic epidermal necrolysis. In: Freedberg I.M., Eisen A.Z., Wolff K., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 644–654
Assier H., Bastuji-Garin S., Revuz J., et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131 (5): 539–543
Rzany B., Mockenhaupt M., Baur S., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49 (7): 769–773
Naldi L., Locati F., Marchesi L., et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126 (8): 1103–1104
Roujeau J.C., Guillaume J.C., Fabre J.P., et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol 1990; 126 (1): 37–42
Schöpf E., Stuhmer A., Rzany B., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127 (6): 839–842
Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13 (4): 623–635
Roujeau J.C., Huynh T.N., Bracq C., et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123 (9): 1171–1173
Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333 (24): 1600–1607
Lebargy F., Wolkenstein P., Gisselbrecht M., et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intens Care Med 1997; 23 (12): 1237–1244
McIvor R.A., Zaidi J., Peters W.J., et al. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996; 17 (3): 237–240
Michel P., Joly P., Ducrotte P., et al. Ileal involvement in toxic epidermal necrolysis (Lyell syndrome). Dig Dis Sci 1993; 38 (10): 1938–1941
Blum L., Chosidow O., Rostoker G., et al. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34 (6): 1088–1090
Wilson E.E., Malinak L.R. Vulvovaginal sequelae of Stevens-Johnson syndrome and their management. Obstet Gynecol 1988; 71 (3 Pt 2): 478–480
Meneux E., Paniel B.J., Pouget F., et al. Vulvovaginal sequelae in toxic epidermal necrolysis. J Reprod Med 1997; 42 (3): 153–156
Paquet P., Pierard G.E. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997; 19 (2): 127–132
Resnick S.D., Elias P.M. Staphylococcal Scalded Skin Syndrome. In: Freedberg I.M., Eisen A.Z., Wolff K., et al., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 2207–2211
Peck G.L., Herzig G.P., Elias P.M. Toxic epidermal necrolysis in a patient with graft-vs-host reaction. Arch Dermatol 1972; 105 (4): 561–569
Villada G., Roujeau J.C., Cordonnier C., et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23 (5 Pt 1): 870–875
Stone N., Sheerin S., Burge S. Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 1999; 24 (4): 260–262
Ford M.J., Smith K.L., Croker B.P., et al. Large granular lymphocytes within the epidermis of erythema multiforme lesions. J Am Acad Dermatol 1992; 27 (3): 460–462
Correia O., Delgado L., Ramos J.P., et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129 (4): 466–468
Villada G., Roujeau J.C., Clerici T., et al. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases [see comments]. Arch Dermatol 1992; 128 (1): 50–53
Paquet P., Nikkels A., Arrese J.E., et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis [see comments]. Arch Dermatol 1994; 130 (5): 605–608
Redondo P., Vicente J., Espana A., et al. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol 1996; 135 (6): 999–1002
Fleischer Jr A.B., Rosenthal D.I., Bernard S.A., et al. Skin reactions to radiotherapy — a spectrum resembling erythema multiforme: case report and review of the literature. Cutis 1992; 49 (1): 35–39
Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282 (5388): 490–493
Mauri-Hellweg D., Bettens F., Mauri D., et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155 (1): 462–472
Wolkenstein P., Charue D., Laurent P., et al. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995; 131 (5): 544–551
Wolkenstein P., Carriere V., Charue D., et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5 (4): 255–258
Shear N.H., Spielberg S.P., Grant D.M., et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105 (2): 179–184
Guillaume J.C., Roujeau J.C., Revuz J., et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell’s syndrome). Arch Dermatol 1987; 123 (9): 1166–1170
Stern R.S., Chan H.L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21 (2 Pt 1): 317–322
Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353 (9171): 2190–2194
Pasricha J.S., Khaitan B.K., Shantharaman R., et al. Toxic epidermal necrolysis. Int J Dermatol 1996; 35 (7): 523–527
Cheriyan S., Patterson R., Greenberger P.A., et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995; 16 (4): 151–155
Heng M.C. Drug-induced toxic epidermal necrolysis. Br J Dermatol 1985; 113 (5): 597–600
Kakourou T., Klontza D., Soteropoulou F., et al. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr 1997; 156 (2): 90–93
Stables G.I., Lever R.S. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993; 128 (3): 357
Parsons J.M. Toxic epidermal necrolysis. Int J Dermatol 1992; 31 (11): 749–768
Revuz J., Penso D., Roujeau J.C., et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123 (9): 1160–1165
Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331 (19): 1272–1285
Halebian P.H., Corder V.J., Madden M.R., et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204 (5): 503–512
Roujeau J.C. Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol 1993; 11 (4): 493–500
Rzany B., Schmitt H., Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991; 71 (2): 171–172
Guibal F., Bastuji-Garin S., Chosidow O., et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995; 131 (6): 669–672
Egan C.A., Grant W.J., Morris S.E., et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40 (3): 458–461
Kamanabroo D., Schmitz-Landgraf W., Czarnetzki B.M. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121 (12): 1548–1549
Sakellariou G., Koukoudis P., Karpouzas J., et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991; 14 (10): 634–638
Chaidemenos G.C., Chrysomallis F., Sombolos K., et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36 (3): 218–221
Frangogiannis N.G., Boridy I., Mazhar M., et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996; 89 (10): 1001–1003
Heng M.C., Allen S.G. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects [see comments]. J Am Acad Dermatol 1991; 25 (5 Pt 1): 778–786
Assier-Bonnet H., Aractingi S., Cadranel J., et al. Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol 1996; 135 (5): 864–866
Jarrett P., Rademaker M., Havill J., et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997; 22 (3): 146–147
Sullivan J.R., Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996; 37 (4): 208–212
Zaki I., Patel S., Reed R., et al. Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. Br J Dermatol 1995; 133 (2): 337–338
Hewitt J., Ormerod A.D. Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol 1992; 17 (4): 264–265
Renfro L., Grant-Kels J.M., Daman L.A. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989; 28 (7): 441–444
Paquet P., Pierard G.E. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999; 198 (2): 198–202
Redondo P., de Felipe I., de la Pena A., et al. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136 (4): 645–646
Paquet P., Pierard G.E. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998; 1 (2): 459–462
Wolkenstein P., Latarjet J., Roujeau J.C., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352 (9140): 1586–1589
Klausner J.D., Kaplan G., Haslett P.A. Thalidomide in toxic epidermal necrolysis. Lancet 1999; 353 (9149): 324
Levy R. Thalidomide in toxic epidermal necrolysis. Lancet 1999; 353 (9149): 324
Revuz J., Roujeau J.C., Guillaume J.C., et al. Treatment of toxic epidermal necrolysis. Creteil’s experience. Arch Dermatol 1987; 123 (9): 1156–1158
Birchall N., Langdon R., Cuono C., et al. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 1987; 16 (2 Pt 1): 368–372
Marvin J.A., Heimbach D.M., Engrav L.H., et al. Improved treatment of the Stevens-Johnson syndrome. Arch Surg 1984; 119 (5): 601–605
Bradley T., Brown R.E., Kucan J.O., et al. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 1995; 35 (2): 124–132
Belfort Jr R., de Smet M., Whitcup S.M., et al. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS. Cornea 1991; 10 (6): 536–538
Lehman S.S. Long-term ocular complication of Stevens-Johnson syndrome. Clin Pediatr (Phila) 1999; 38 (7): 425–427
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fritsch, P.O., Sidoroff, A. Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Am J Clin Dermatol 1, 349–360 (2000). https://doi.org/10.2165/00128071-200001060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001060-00003